serine has been researched along with Endometrial Neoplasms in 8 studies
Serine: A non-essential amino acid occurring in natural form as the L-isomer. It is synthesized from GLYCINE or THREONINE. It is involved in the biosynthesis of PURINES; PYRIMIDINES; and other amino acids.
serine : An alpha-amino acid that is alanine substituted at position 3 by a hydroxy group.
Endometrial Neoplasms: Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The study investigated the expression of p53 protein phosphorylated at serine 20 (Ser20) and Ser392 and the association between clinicopathological parameters of ovarian neoplasms with respect to p53 protein overexpression." | 7.75 | Expression of p53 protein phosphorylated at serine 20 and serine 392 in malignant and benign ovarian neoplasms: correlation with clinicopathological parameters of tumors. ( Bar, JK; Gryboś, M; Noga, L; Rabczyńki, J; Słomska, I, 2009) |
| " The study investigated the expression of p53 protein phosphorylated at serine 20 (Ser20) and Ser392 and the association between clinicopathological parameters of ovarian neoplasms with respect to p53 protein overexpression." | 3.75 | Expression of p53 protein phosphorylated at serine 20 and serine 392 in malignant and benign ovarian neoplasms: correlation with clinicopathological parameters of tumors. ( Bar, JK; Gryboś, M; Noga, L; Rabczyńki, J; Słomska, I, 2009) |
| "Endometrial cancer is strongly associated with obesity and dysregulation of metabolic factors such as estrogen and insulin signaling are causal risk factors for this malignancy." | 1.62 | Prospective analysis of circulating metabolites and endometrial cancer risk. ( Agnoli, C; Allen, N; Amiano, P; Biessy, C; Christakoudi, S; Colorado-Yohar, SM; Crous-Bou, M; Dimou, N; Dossus, L; Fortner, R; Gram, IT; Gunter, MJ; Gurrea, AB; Heath, AK; Kaaks, R; Keun, HC; Kouloura, E; Lécuyer, L; Mattiello, A; Merritt, MA; Nøst, TH; Palli, D; Rinaldi, S; Rothwell, JA; Sacerdote, C; Sánchez, MJ; Schmidt, JA; Schulze, MB; Severi, G; Siskos, AP; Travis, RC; Tsilidis, KK; Tumino, R; Vermeulen, R; Viallon, V; Weiderpass, E, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (62.50) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (37.50) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, X | 1 |
| Ma, H | 1 |
| Ma, L | 1 |
| Li, K | 1 |
| Kang, Y | 1 |
| Troisi, J | 1 |
| Mollo, A | 1 |
| Lombardi, M | 1 |
| Scala, G | 1 |
| Richards, SM | 1 |
| Symes, SJK | 1 |
| Travaglino, A | 1 |
| Neola, D | 1 |
| de Laurentiis, U | 1 |
| Insabato, L | 1 |
| Di Spiezio Sardo, A | 1 |
| Raffone, A | 1 |
| Guida, M | 1 |
| Dossus, L | 1 |
| Kouloura, E | 1 |
| Biessy, C | 1 |
| Viallon, V | 1 |
| Siskos, AP | 1 |
| Dimou, N | 1 |
| Rinaldi, S | 1 |
| Merritt, MA | 1 |
| Allen, N | 1 |
| Fortner, R | 1 |
| Kaaks, R | 1 |
| Weiderpass, E | 1 |
| Gram, IT | 1 |
| Rothwell, JA | 1 |
| Lécuyer, L | 1 |
| Severi, G | 1 |
| Schulze, MB | 1 |
| Nøst, TH | 1 |
| Crous-Bou, M | 1 |
| Sánchez, MJ | 1 |
| Amiano, P | 1 |
| Colorado-Yohar, SM | 1 |
| Gurrea, AB | 1 |
| Schmidt, JA | 1 |
| Palli, D | 1 |
| Agnoli, C | 1 |
| Tumino, R | 1 |
| Sacerdote, C | 1 |
| Mattiello, A | 1 |
| Vermeulen, R | 1 |
| Heath, AK | 1 |
| Christakoudi, S | 1 |
| Tsilidis, KK | 1 |
| Travis, RC | 1 |
| Gunter, MJ | 1 |
| Keun, HC | 1 |
| Bar, JK | 1 |
| Słomska, I | 1 |
| Rabczyńki, J | 1 |
| Noga, L | 1 |
| Gryboś, M | 1 |
| Shah, YM | 1 |
| Rowan, BG | 1 |
| Bryant, W | 1 |
| Snowhite, AE | 1 |
| Rice, LW | 1 |
| Shupnik, MA | 1 |
| Vernez, M | 1 |
| Hutter, P | 1 |
| Monnerat, C | 1 |
| Halkic, N | 1 |
| Gugerli, O | 1 |
| Bouzourene, H | 1 |
| Ollila, S | 1 |
| Dermadi Bebek, D | 1 |
| Greenblatt, M | 1 |
| Nyström, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 0 Pharmacodynamic Study of Dasatinib in Women With Newly Diagnosed Endometrial Cancer[NCT01482728] | Early Phase 1 | 12 participants (Actual) | Interventional | 2012-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 other studies available for serine and Endometrial Neoplasms
| Article | Year |
|---|---|
RNA-binding protein with serine-rich domain 1 regulates microsatellite instability of uterine corpus endometrial adenocarcinoma.
Topics: Carcinoma, Endometrioid; Cell Line, Tumor; Endometrial Neoplasms; Female; Humans; Microsatellite Ins | 2021 |
The Metabolomic Approach for the Screening of Endometrial Cancer: Validation from a Large Cohort of Women Scheduled for Gynecological Surgery.
Topics: Early Detection of Cancer; Endometrial Neoplasms; Female; Glutamic Acid; Glyceraldehyde 3-Phosphate; | 2022 |
Prospective analysis of circulating metabolites and endometrial cancer risk.
Topics: Aged; Biomarkers, Tumor; Body Mass Index; Carnitine; Case-Control Studies; Endometrial Neoplasms; Fe | 2021 |
Expression of p53 protein phosphorylated at serine 20 and serine 392 in malignant and benign ovarian neoplasms: correlation with clinicopathological parameters of tumors.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Hu | 2009 |
The Src kinase pathway promotes tamoxifen agonist action in Ishikawa endometrial cells through phosphorylation-dependent stabilization of estrogen receptor (alpha) promoter interaction and elevated steroid receptor coactivator 1 activity.
Topics: Antineoplastic Agents, Hormonal; Blotting, Western; Cell Line, Tumor; Chromatin Immunoprecipitation; | 2005 |
The estrogen receptor (ER)alpha variant Delta5 exhibits dominant positive activity on ER-regulated promoters in endometrial carcinoma cells.
Topics: Cell Line, Tumor; Dimerization; Endometrial Neoplasms; Epidermal Growth Factor; Estradiol; Estrogen | 2005 |
A case of Muir-Torre syndrome associated with mucinous hepatic cholangiocarcinoma and a novel germline mutation of the MSH2 gene.
Topics: Adenocarcinoma, Mucinous; Adenoma; Adult; Brain Neoplasms; Carcinoma; Cholangiocarcinoma; Colorectal | 2007 |
Uncertain pathogenicity of MSH2 variants N127S and G322D challenges their classification.
Topics: Asparagine; Aspartic Acid; Biliary Tract Neoplasms; Blotting, Western; Colorectal Neoplasms, Heredit | 2008 |